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Abstract: Urotensin II and Urotensin-II receptors are important molecular factors 
that regulate vasoconstriction and all the diseases that are linked to abnormalities 
in blood pressure regulation (i.e.: hypertension, kidney diseases, cirrhosis etc.). 
Recently, Urotensin II and its receptor have also been involved in metabolic syn-
drome, diabetes and schizophrenia. Recent strong findings suggest that Uro-
tensin II and its receptor are involved in the onset and development of different 
epithelial cancers. Indeed, it was reported that cell growth, motility and invasion 
in human breast, bladder, prostate, colorectal and glioblastoma cancer cells were 
regulated by Urotensin II and Urotensin-II receptor axis. This axis also regulated 
focal adhesion kinase and small Guanosine-5'-triphosphate binding proteins that 
likely had a role in motility and invasion mediated by Urotensin-II receptor. Additionally, its expres-
sion on tumour tissues is variably associated to the prediction of the clinical outcome of the patients 
and it can be considered an alternative molecular marker to be used as prognostic factor in human 
cancers. In conclusion, a new weapon in the treatment of human cancers is highlighting a new sce-
nario for the future. 
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INTRODUCTION 
Urotensin-II (U-II) has vasoactive properties, as well as 
Endothelin-1 (ET-1) and Adrenomedullin (AM), which pos-
sesses a significant vasoconstrictor activity, more remarkable 
than ET-1 in terms of potency [1]. U-II acts as 
a potent vasoconstrictor in humans [1, 2], although it has 
been originally isolated from urophisis of teleostean fish 
Gillichthys mirabilis [3, 4]. U-II has a somatostatin-like 
structure and has been mainly studied for its vasoactive 
physiological role, turning out to be an important molecule 
for the understanding and treatment of mechanisms that sup-
port diseases such as hypertension [1, 3, 5, 6]. The biosyn-
thesis of this peptide-hormone starts from a pre-pro-protein 
subjected to several post-translational processes mediated by 
proteasesnot yet well identified. Precursors of the active iso-
forms (pro-UT-1 and pro-UT-2) have not yet been correlated 
to specific biological effects and it is not clear whether these 
precursors could generate other molecules of biological in-
terest. 
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Human isoform of U-II is an undecapeptide and its C-
term region is arranged in a cyclic esapeptide sequence due 
to a disulfide bridge between two cysteine residues [2]. To 
date, diverse U-II isoforms have been isolated from fish to 
amphibious, revealing, by structural analysis investigation, 
the high conservation of C-term region that is a site of prime 
importance for the function of the peptide [7]. Recently, a 
new peptide has been isolated from the rat, which is structur-
ally akin to U-II due to equal cyclic C-term portion, 
A[CFWKYC]V, and for this reason named Urotensin-II re-
lated peptide (URP). This peptide has shown high affinity for 
human U-II receptor, as well as a very similar biological 
activity [8]. U-II interacts with a specific receptor that was 
investigated for its remarkable scentific interest. This recep-
tor has been first identified as G protein coupled-receptor 
(GPR)-14 [9-11], an orphan receptor that belongs to GPCRs 
family [12]. Originally discovered in 1999 by Ames et al. in 
the rat, Urotensin-II receptor, also known as UT receptor 
(UTR), has exhibited structural analogies with somatostatin, 
opiate and galantine receptors [13]. Grieco and co-workers 
have studied the way somatostatin (SST)-14 and corti-
costatin-14 are able to activate UTR albeit in elevated con-
centration, but they have proved to be irrelevant towards 
physiological effects [2]. Moreover, this study has confirmed 
the role of U-II as the unique endogenous ligand that binds 
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UTR with high affinity [2]. In humans, the minimum active 
sequence of U-II (hU-II) is represented by the fragment 4-11, 
H-Asp-[Cys-Phe-Trp-Lys- Tyr-Cys]-Val-OH, hU -II(4-11), 
characterized by potency and efficacy comparable to native 
whole sequence. U-II and UTR are expressed everywhere in 
human body. The function of these peptides is yet object of 
study for many tissue types; in other tissue types this func-
tion is only hypothesized. Particularly, elevated expression 
of U-II and UTR mRNA has been observed in cardiac tissue 
(atrial and ventricular myocytes, fibroblasts), arteries 
(mainly aorta), endothelial cells and smooth muscle cells 
(especially in vessels), liver, kidney and endocrine tissue [11, 
14-16]. By immunoreactivity test, U-II has also been found 
in both central nervous tissue [17-23] and spinal cord motor 
neurons, intervening in neuromuscolar trasmission [24]. In 
fact, in the brainstem and spinal cord, cholinergic neurons 
have been found to express both UII and URP genes [25]. U-
II and URP work through the interaction with a G-coupled 
protein receptor without significant differences in the affinity 
and signal transduction pathways activated. In the details, the 
connection of U-II with its receptor leads to the activation of 
Gq protein that activates protein kinase C (PKC), a serine 
threonine kinase, calmodulin and phospholipase C (PLC). 
PLC induces the formation of inositol trisphosphate (IP3) 
and diacylglycerol (DAG) that once activated, determines 
calcium release from sarcoplasmic reticulum, with conse-
quent increase of intracellular calcium concentration. This 
increase is responsible for the vast majority of the effects 
linked to UTR activation including PKC stimulation [26, 
27]. The interaction U-II/UTR would have vasoconstrictor 
effects mediated by activation of myosin light chain kinase 3 
(MLCK), extracellular signal regulated kinase (ERK), a 
kinase regulating cell proliferation and survival, RhoA/Rho 
kinase (ROCK), as well as by PKC mediated-pathway that 
was previously described [28, 29]. Finally, Protein kinase 
B/Glycogen synthase kinase 3 beta (Akt/GSK-3beta) path-
ways and beta-catenin stabilization play an important role in 
the UII-mediated hypertrophy [30, 31]. Apart from its vascu-
lar effects, U-II causes contraction of smooth muscle cells of 
human small respiratory tracts and cat and mouse bronchial 
tubes [20, 32]. Transductional pathways and functional role 
of UTR are represented in Figs. (1 and 2), respectively. 
UTR AND DISEASES 
The possible role that U-II and UTR could have in pro-
moting a remarkable number of diseases, also systemic, is 
becoming an interesting matter in scientific community. 
Pulmonary arterial hypertension (PAH) is a fatal disease 
for which any progress in the treatment is decisive. It has 
been recently reported a study that compares the standard 
therapy based on ET-1 inhibitor bosentan with different dos-
ages of U -II inhibitor palosuran [33] and a statistically sig-
nificant difference for mean pulmonary arterial pressure 
(mPAP), U-II, ET1 levels, and pulmonary vascular pathol-
ogy has been observed. 
The authors concluded that U-II inhibitor and standard 
therapy showed similar efficiency [34]. Thirty-three pregnant 
women with hypertensive disorders and twenty-two healthy 
controls have been recently enrolled. 
The authors found positive correlation between U-II and 
endoplasmic reticulum stress (ERS) markers expression level 
in placental tissues that also correlated with systolic blood 
pressure and proteinuria levels [35]. It was also reported a 
role for UTR in the determination of hypertrophyc cardio-
myopathy in a rat model. In fact, the results of this study 
suggested a key role for U-II and the cyclic adenosine mo-
nophosphate-protein kinase A (cAMP-PKA) pathway in 
pressure overload-induced myocardial fibrosis [36]. On these 
bases, a highly potent UTR antagonist showed anti-
hypertrophic effects both in rat models of infarction and in 
mouse model of pressure overload hypertrophy [37]. On the 
other hand, it was previously reported the involvement of β-
arrestin in UTR-induced Epidermal Growth Factor Receptor 
(EGFR) trans-activation [38] that protected against pressure 
overload-induced hypertrophy [39]. Based on its function on 
endothelial cells, UTR expression was also studied in rela-
tion to human corpus cavernosous (HuCC) function. In fact, 
UTR was found in human and rat corpus cavernosum. In 
HuCC UTR was expressed on endothelial cells. U-II induced 
a significant endothelium- and -NO-dependent relaxation 
of HuCC strips. Moreover, pressure in anesthetized rats cor-
pus cavernosum increased significantly [40]. On these bases, 
two agonists of U-II were injected in the Rat Corpus Caver-
nosous (RCC) and the intracavernous pressure (ICP) was 
measured. 
Intracavernously injected U-II (0.03-1 nmol) and the 
agonists P5U (0.03-1 nmol) or UPG84 (0.03-1 nmol), in-
creased ICP. Particularly, ICP was significantly modulated 
by P5U compared to U-II [41]. The elevated expression of 
U-II in kidney has led to make a hypothesis of its patho-
physiological role in glomerular filtration [42]. It was re-
cently discovered that UII-induced store-operated Ca(2+) 
entry (SOCE) causes contraction in murine glomerular me-
sangial cells (GMC) and that UTR [43] activation recruits 
regulator of G-protein signaling (RGS2) to GMC membrane 
that negatively regulates UTR transduction pathway [25]. On 
the other hand, genetic polymorphisms of U-II/UTR axis 
have not been found to be associated to blood pressure con-
trol regulated by renal function [44]. Moreover, U-II and 
UTR are more highly expressed in tubules than in GMCs 
suggesting its role in the filtration mechanisms. Because of 
the abundant U-II expression in sclerotic areas, U-II may be 
related with glomerular sclerosis for its inflammatory proper-
ties or by acting as a growth factor [45].  
These experimental observations lead to consider U-II as 
hypertensive disease multi-systemic mediator. Indeed, as 
reported, it would act at multiple levels: through the induc-
tion of vasoconstriction, proliferation of vascular smooth 
muscle cells by inducing myocardial hypertrophy; addition-
ally it is involved in regulation mechanisms of glomerular 
filtration and glomerulosclerosis. In this last case, U-II could 
be considered as a factor that links hypertension to the de-
velopment, over time, of glomerular sclerosis, by producing 
a vicious circle that promotes hypertension itself. 
Furthermore, there is an important correlation between 
liver disease and U-II expression levels. Indeed, in cirrhotic 
patients U-II mRNA expression and levels of protein in 
plasma increase in relation to the severity of disease and por-
tal pressure levels [46, 47]. Consequently, serum U-II may 
be used as surrogate marker of portal hypertension and, in 
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Fig. (1). Transductional pathways of Urotensin-II Receptor. PKC: protein kinase C; ERK: extracellular signal-regulated kinase; ROCK: 
RhoA/Rho kinase; PLC: phospholipase C; IP3: inositol-1,4,5-trisphosphate; MLCK: myosin light-chain kinase; NADPH: nicotinamide 
adenosine dinucleotide phosphate; ROS: reactive oxygen species; c-Src: Src kinase; UTR: UII receptor; UII: Urotensin-II; Gq/i, subtype of G 
protein; MAPK: mitogen-activated protein kinase; FAK: focal adhesion kinase; cAMP: cyclic adenosine monophosphate; AMP: adenosine 
monophosphate; PKA: protein kinase A; Akt: Protein kinase B. 
 
 
Fig. (2). Correlation between kinases activated by Urotensin-II Recptor and their biological functions. UII: Urotensin-II; UTR: Urotensin-II 
Receptor; MLCK: myosin light-chain kinase; PKC: protein kinase C; ERK: extracellular signal-regulated kinase; MEK: Mitogen-activated 
protein kinase; MAPK: mitogen-activated protein kinase; Akt: Protein kinase B; FAK: focal adhesion kinase; ROCK: RhoA/Rho kinase. 
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addition to parameters used for Child Pugh evaluation and 
Model for End-Stage Liver Disease (MELD) score, it could 
be useful to identify better patients with a severe hepatopa-
thy. In this way, a reconsideration of the current prognostic 
evaluation, applied to patients with liver diseases, may be 
possible.  
Nowadays, the etiology of liver disease is radically 
changing and we are witnessing a constant increase of pa-
tients affected by metabolic syndrome and liver steatosis 
[48]. Recently, a possible role of U-II in determining meta-
bolic syndrome [49] has emerged. In patients with type 2 
diabetes mellitus an elevated level of [50] U-II has been ob-
served both in plasma and urina [13, 51, 52]. On these bases, 
obese ob/ob mice treated with the UTR antagonist SB657510 
showed significant improvements in glucose levels, blood 
pressure, hyperlipidemia, cardiac function, intracellular 
Na(+) and Ca(2+) and a decrease in weight and so-
dium/hydrogen exchanger 1 (NHE- 1) protein expression 
compared with vehicle [53] (P<0.05). These data demon-
strate the possible translation of experimental results in the 
pharmacological treatment of metabolic syndrome [54], 
since they demonstrate that switching off the signal activated 
by U-II, through a therapy with antagonist for UTR, leads to 
an improvement of important indices of metabolic homeosta-
sis, as well as to be able to take position against an important 
component of metabolic syndrome: arterial hypertension. In 
the last years, the same authors have demonstrated that in 
mice knockout for UII gene (UIIKO) body mass, visceral fat, 
blood pressure and an increase of insulin and glucose toler-
ance significantly decreased compared to wild-type mice 
[55, 56].  
For a summary of the evidence of UTR involvement in 
non neoplastic diseases (Table 1). 
In recent years, another important function of U-II and its 
receptor has been investigated: the ability to modulate cell 
proliferation, invasion, motility and metastatization of tu-
mour cells. In fact, many researchers have attempted to fig-
ure out the mechanisms by which these peptides could pro-
mote cell proliferation in tumour diseases. For instance, an 
important role is carried out in adrenocortical tissue in de-
termining primary aldosteronism; in lymphangioleiomyoma-
tosis (LAM) cells in patients with LAM; colon and prostate 
adenocarcinoma, bladder carcinoma; in rat models with di-
ethylnitrosamine-induced hepatic precancerous lesions [57] 
and human hepatocarcinoma (HCC), as well as breast carci-
noma [58-65]. 
ROLE OF U-IIUTR AXIS IN THE REGULATION 
OF CANCER PROLIFERATION AND DEVELOP-
MENT 
The role of peptides with vasoactive properties, including 
ET-1 and U-II, has been [66] investigated for a long time. 
About these peptides, it has been recently studied the possi-
bility to induce cell proliferation by pathways associated 
with their receptors. In 2000 some groups of researchers con-
firmed the expression of these molecules for a few human 
cancer types [67, 68]. In a study by Takahashi et al. [69], it 
has been studied the expression of these three proteins and 
their related receptors in eight tumoral cell lines: glioblas-
toma (T98G), neuroblastoma (IMR-32, NB69), choriocarci-
noma (BeWo), adrenocortical (SW-13), colon (DLD-
1), cervical carcinoma (HeLa, VMRC-RCW). 
The analysis with RT-PCR has demonstrated mRNA ex-
pression of ET-1 in seven cell lines, with the exception of 
BeWo. mRNA of endothelial “type a” receptor endothelin 
(ETa) is expressed in NB69, IMR-32, T98G cell lines and 
weakly in the resting cells. “Type b” receptor endothelin 
(ETb) is found in IMR-32, NB69, BeWo cells and slightly in 
T98G and HeLa cells. 
Immunoreactivity for ET-1 has been observed in six out 
of eight cell lines. Cells have also been treated with antago-
nists of endothelin receptor: BQ-610, antagonist of ETa and 
BQ788, blocking ETb receptor. This has allowed identifying 
which of the two receptors is mainly involved in the mecha-
Table 1. Urotensin-II Receptor involvement in non neoplastic diseases. 
Disease Involvement Evidence Drug Ref  
Pulmonary arterial hyperten-
sion 
Evaluation trial of U-II inhibitors vs. ET-1 inhibitor bosentan Palosuran [34] 
Pulmonary arterial hyperten-
sion 
Positive correlation between U-II and endoplasmic reticulum stress mark-
ers expression level in placental tissues 
ND [35] 
Hypertrophyc cardiomyopathy Myocardial fibrosis in chronic pressure-overload rats Palosuran [36-39] 
Erectile dysfunction Modulation of rat Intra-Corpus Cavernosus pressure P5U and UPG84 [41] 
Kidney disease Role in the progression of glomerular sclerosis ND [45] 
Cirrhosis 
U-II mRNA expression and levels of protein in plasma increase in relation 
to the severity of disease and portal pressure levels 
ND [46, 47] 
Metabolic syndrome 
obese ob/ob mice treated with the UII receptor antagonist showed amelio-
rated syndrome parameters 
UII gene knockout in mice (UIIKO) induced a significant decrease ofme-
tabolic syndrome severity 
SB657510 [55] 
U-II: Urotensin-II; ET-1: Endothelin-1; ND: not detected. 
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nism of activation of cell proliferation. This research has led 
to three important results: i) ET-1 is produced by different 
tumoral types and can act as autocrine and paracrine growth 
stimulant for tumoral cells through a signal mainly mediated 
by ETa receptor activation; ii) AM is produced and secreted 
by various endocrine and non-endocrine cancers and it has a 
stimulating effect on tumoral cell growth; iii) U-II required 
additional studies with the aim to clarify its role in prolifera-
tive pathologies. Over time new proofs have been acquired 
about its role in promoting proliferative diseases carried out 
by U-II/UTR, which have led to consider these molecules as 
important pharmachological targets for future antitumoral 
therapies [67-69]. 
PROSTATE CANCER 
Adenocarcinoma is the most frequent primary cancer in 
the prostate with an incidence very variable in relation to 
different epidemiological data analyzed; however, these 
studies confirm an increase of prevalence in relation to the 
advance of the age. The severity of prostate carcinoma is 
extremely variable, since there are conditions completely 
benign and other with a very severe prognosis [70-72]. 
Nowadays, the main prognostic index is Gleason’s score, 
which conveys the experience of pathologist [73]. Recently, 
Grieco et al. have investigated the potential role of U-II 
and UTR in prostate adenocarcinoma [60]. Particularly, the 
objectives of the study were: i) to evaluate in vivo UTR ex-
pression on prostate tissue samples and in vitro on the three 
classic cell lines for the study of prostate carcinoma (andro-
gen- independent DU145, PC3; androgen-dependent 
LNCaP); ii) to study in vitro the effects of U -II and Urantide 
on the cell growth, migration and invasion of DU145, PC3 
and LNCaP cells. UTR expression evaluated with Western 
Blot was higher in LNCaP cells, and lower in androgen-
independent DU145 and PC3 cells. UTR mRNA expression 
evaluated by RT- PCR was correspondingly higher in 
LNCaP cells than in the other two lines. UTR expression has 
also been evaluated with immunohistochemistry on 195 
prostate tissue samples deriving from biopsy or prostatec-
tomy for adenocarcinoma. This protein was moderately ex-
pressed in benign hypertrophic prostate tissues, whereas in 
cancer its expression showed a variation on the basis of dis-
ease grading. Specifically, UTR was expressed with elevated 
intensity in well differentiated prostate adenocarcinoma, 
Gleason score <7, whereas it was less expressed or even ab-
sent in adenocarcinomas with a more advanced grading, 
Gleason >7. It was concluded that, like Gleason score, also 
the evaluation of tissue expression of UTR represents an 
important prognostic index; particularly the lack of expres-
sion, evaluated by survival statistical models, confirmed a 
worse long term prognosis [60]. To investigate the role of 
UTR in cell motility and invasion, LNCaP cell line 
was treated with Urantide. 
Both quantitative and qualitative analysis for the measure 
of these parameters have been performed by scanning elec-
tron microscope (SEM) and computer assisted optical mi-
croscopy. After treatment with Urantide, the analysis of the 
outcomes has demonstrated a dose-depedent decrease of the 
area occupied by migrating and invading cells. Urantide also 
has effects on adhesion factors and many of these regulate 
processes of extracellular matrix/cytoskeleton interaction 
responsible for cell-proliferation, migration and invasion. 
Focal adhesion kinase (FAK) is a non receptorial tyrosine 
kinase protein, which promotes both cell motility and inva-
sion. Activation of FAK increased in LNCaP cells after in-
duction of migration. The treatment with Urantide for 24 h 
reduced in a significant fashion pFAK expression in these 
cells (30-50%), as well as cluster of differentiation (CD)61 
and CD11 expression (40%) (integrin αvβ3, integrin β2), 
both involved in processes of cell adhesion. Similar out-
comes were obtained with UTR gene silencing obtained 
through cell transfection with a short hairpin RNA (shRNA). 
However, the association of Urantide with shRNA did not 
cause effects higher than the treatment with either Urantide 
or shRNA alone. Finally, the analysis of survival statistical 
models confirmed that patients with a higher UTR expres-
sion level (Gleason score <7) have a life expectancy better 
than those with lower UTR expression (Gleason  >7) [60]. 
These data were confirmed by another study in which 58 
subjects with radical prostatectomy were enrolled. Multivari-
ate analysis suggested that Gleason upgrading and pathology 
upstaging correlated with low UTR expression (OR: 10.3, 
95% CI: 1.55-68.4 and OR: 11.1; 95% CI: 1.23-100.48, re-
spectively) [74]. UTR expression level, evaluated by using 
immunohistochemistry, represents a prognostic marker inde-
pendent of Gleason score. This is useful to differentiate bet-
ter advanced cancer types, since this parameter is independ-
ent of pathologist experience. 
Moreover, the explanation of lower UTR expression in 
advanced stages may be due to the fact that undifferentiated 
carcinoma could benefit from signals different from that me-
diated by UTR for the activation of proliferative and metas-
tatic mechanisms,either through intracellular Ca+2 increase or 
constitutive FAK activation and mitogen-activated protein 
kinase (MAPK). This is related to a higher cell atypia and 
different gene expression, also confermed by simultaneous 
loss of androgenic dependence.  
BLADDER CANCER 
Transitional cell carcinoma of bladder is classified in two 
main types, based upon both histology and prognosis: non-
muscle invasive bladder cancer (NMIBC) and muscle inva-
sive bladder cancer (MIBC), and it is the fourth among the 
most frequent malignant neoplastic diseases worldwide [75]. 
Currently, histopathological stage and grading are the most 
important prognostic factors for bladder cancer [76]. Despite 
these two parameters are used for a long time, they depend on 
the experience of the pathologist who analyzes samples [77]. 
Therefore, alternative prognostic markers are strongly war-
ranted. In a recent study, Franco et al. [62] have investigated 
the role of U-II/UTR-related pathways on the ability to modu-
late proliferation, migration and invasion of different transi-
tional cancer cell lines. Moreover, the authors have evaluated 
in vivo the expression levels of UTR in order to attribute a 
prognostic value, predictive of relapse and able to differentiate 
NMIBC from MIBC. The evaluation of UTR expression lev-
els has been carried out in vivo on samples from 159 patients. 
UTR expression was higher in NMIBC than MIBC; moreover, 
MIBC patients showed a higher number of negative samples 
for UTR expression than NMIBC. 
Relapses have been observed in 75 patients (47%). Re-
current cancer grading has been the same of primary cancers 
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in 71 patients, whereas 4 patients have demonstrated a grad-
ing progression. Elevated UTR expression was related to 
cancer grading, being higher in low grade than in high grade 
cancers. Moreover, UTR expression was lower in reccurent 
cancer, also highlithing a prognostic role for UTR.It has also 
been recorded a significant association between low UTR 
expression and the short time of recurrence. This observation 
may lead to a whole revision of prognostic indices, evaluated 
at the moment of diagnosis of this type of neoplasia, through 
biopsy. An early diagnosis in patients with a higher risk of 
disease relapse could lead to a new planning of the current 
method of post-surgery follow-up of tumour ablation with 
significant advantages in terms of lives and health econom-
ics. 
Thereafter, the biological effects of U-II agonist/ antago-
nist peptides (U-II, UPG84/UPG83, UPG85, Urantide) were 
evaluated in vitro. The treatment of MCR, RT112, T24 and 
HT1376 bladder cancer cell lines with U-II for 72 h did not 
induce growth stimulation. On the other hand, the superago-
nist UPG84 determined growth inhibition in all assessed cell 
lines, with the exception of RT112. The authors have hy-
pothesized that this effect was likely due to receptor inter-
nalization and consequent UTR post-transductional down-
regulation. Indeed, UTR once activated, also promotes beta-
arrestin translocation to the cell membrane. Beta-arrestin is 
involved in the internalization of the receptor and prevents 
the coupling of G-protein from its receptor, both blocking G 
protein-mediated (Gq, Gi, Go, G13) pathways and leading to 
a fast down-regulation of UTR effector system [13]. Uran-
tide determined cell growth inhibition in RT112 and T24 
cells, whereas it did not induce significant effects in both 
HT1376 and MCR cells [62]. To evaluate effects of UTR on 
both motility and invasion, T24 e RT112 cells were incu-
bated for 48 h with Urantide, that induced an about 35% and 
50% reduction of migratory and invasive capacity, resepec-
tively. Moreover, cell transfection of shRNA for UTR 
caused an inhibiting effect of either 45% or 56% on motility 
and invasion, respectively. However, the treatment of 
shRNA-UTR-transfected cells with Urantide did not deter-
mine additional inhibition. This last effect could be ex-
plained by UTR downregulation from cell surface, confirm-
ing that the addition of Urantide is able to produce an inhibi-
tory biological effect,but only through interaction with its 
receptor and not with other surface structures [62]. 
DIGESTIVE SYSTEM CANCER 
Hepatocellular Carcinoma 
The occurrence of HCC is generally due to a chronic dis-
ease that, through chronic tissue inflammation, slowly leads 
to parenchymal damage, progressing in sequential gene hits, 
which induce cancer formation and development. In fact, 
after 15-20 years, the continuous parenchymal damage leads 
to cirrhosis and HCC development. 
U-II and UTR are found in all human tissues, such as 
liver [14, 78-80] which would be also responsible for U-II 
plasma levels [81]. In fact, high U-II levels in plasma were 
found in chronic hepatic disease [82]. In a study by Wang et 
al., performed on mice [63], an association between pre-
cancerous lesions induced by the exposure to diethylnitrosa-
mine (DEN) and the level of plasmatic and tissue UTR and 
U-II expression was investigated. The aim of the report was 
the identification of the intracellular signaling pathways of 
UTR that could mediate cell proliferation, as well as to 
evaluate if exposure of mouse oval cells to U-II in vitro was 
able to stimulate their growth. The authors induced pre-
cancerous lesions in animal liver by DEN introduction in 
abdominal cavity. At the end of the treatment, mice were 
sacrificed, liver was removed and blood was collected; these 
samples were used in order to confirm the presence of pre-
cancerous lesions. Higher U-II and UTR liver tissue expres-
sion was recorded in diseased mice if compared to normal 
animal group and similar results were also found for blood 
circulating U-II levels. Analysis with real time Polymerase 
Chain Reaction (RT-PCR) showed anabout 101.2% increase 
of UTR mRNA compared to controls. The authors evaluated, 
in vitro, if the incubation of HOCs cells with U-II was able 
to induce cell proliferation. HOCs cells represent a useful 
model for the study of HCC in vitro. After 24 h incubation 
cell growth stimulation was observed. Finally, in order to 
assess the trasductional pathways involved, cells were incu-
bated at different times with U-II together with PKC (Cal-
phostin C) or mitogen-activated protein kinase kinase 
(MEK) (PD98059) or MAPK (SB203580) inhibitors. The 
results suggested that the effects on cell growth inhibition 
were PKC and MEK- dependent. Yu et al. [64] have recently 
reported both higher mRNA and protein expression of U-II 
and UTR in cancer tissue than in healthy tissues of the same 
patients. These data were paralleled by higher levels of PKC, 
extracellular-signal-regulated kinase (ERK) and p38 MAP 
kinase phosphorylation in cancer samples if compared to 
healthy ones. These results were reproduced also in vitro in 
HCC BEL-7402 cells that expressed high levels of UTR. The 
incubation of BEL-7402 cells with U-II increased phos-
phorylated PKC, ERK, and p38 MAPK and stimulated cell 
growth. Finally, BEL-7402 cells were incubated with U-II 
with or without PKC, ERK, p38 MAPK inhibitors of 
GF109203x, PD184352, SB203580 respectively, in order to 
confirm if this phosphorylation was required to induce cell 
proliferation. The growth-promoting effect induced by U-II 
was partially abolished by the use of GF109203x, 
PD184352, SB203580, confirming that the pathways medi-
ated by PKC, ERK, and p38 MAPK are, at least in part, in-
volved in U-II-induced cell proliferation. The high level of 
serum U-II that can be observed in chronic liver diseases, 
may lead to hypothesize that liver pathology, especially cir-
rhosis, could also act through a mediation carried out by U-II 
in determining neoplastic pathology. For this reason, the 
intervention with therapies in the break of this ring of con-
nection,could outline the prevalence of HCC in patients with 
liver diseases again. 
Colorectal Carcinoma 
Colon cancer is the second deadly tumour in men after 
lung cancer and third in women after breast and lung cancer 
[83]. Colon adenocarcinoma causes death in approximately 
25 subjects out of 100,000/year [84, 85], and it represents a 
great epidemiological and economic problem for health and 
social expenses; therefore, the study of new preventive and 
therapeutic strategies is strongly warranted. Patient survival 
and therapeutic strategies depend on the disease stage at 
the moment of diagnosis. 
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Federico et al. [59] have demonstrated, by using Western 
Blotting, that UTR is expressed in all four evaluated colorec-
tal cancer cell lines (LOVO, HT-29, SW620, COLO and 
WIDR) with higher expression in WIDR cells. Tissue sam-
ples of 114 patients were analyzed with immunohistochemis-
try, respectively 52 men and 62 women divided into 48 pa-
tients with adenocarcinoma, 21 with adenoma and 45 with 
normal colon tissue. UTR expression was low in normal co-
lon tissue (5-30%), medium in adenomatous polyps (30-
48%), and high in adenocarcinomas (65-90%). Moreover, in 
well differentiated (i.e. G1) cancer, 85% of cells was UTR 
positive compared with poorly differentiated (i.e. G3) can-
cers that showed 70% of UTR positive. UTR mRNA expres-
sion was 3-fold higher in patients with adenomatous polyps 
than in control tissues, and up to 8-fold in patients with ade-
nocarcinoma. Normal colon tissue fragments extracted in 
patients with adenocarcinoma showed UTR expression lev-
els comparable to the expression of patients without cancer. 
The biological effects of U-II and its antagonistic or agonis-
tic peptides were also investigated on colorectal cancer cell 
lines. U-II increased cell growth in HT29, LOVO and WIDR 
lines by 20%, 30% and 60% respectively, whereas urantide 
induced an about 35%, 20% and 40% cell growth inhibition 
in LOVO, HT29 and WIDR lines, respectively. UPG83 and 
UPG85 also inhibited cell proliferation of HT29 cells by 
30% and 35%, of LOVO cells by 45% and 50%, of WIDR 
cells by 45% and 55%, respectively. High U-II concentra-
tions of 100 nM for 72 h caused an about 60% growth inhibi-
tion likely due to receptor down-regulation that can make 
cells insensitive to proliferative effects induced by the acti-
vation of UTR pathway. U-II, regulating Ca+2 intracellular 
levels, can be responsible for changes of tumour cell cy-
toskeleton that is required for metastatic process. On these 
bases, the authors evaluated the effects derived from UTR 
block with either urantide or shRNA on migration and inva-
sion of colon cancer cell lines (LOVO and WIDR). shRNA 
led to an efficient reduction of UTR expression on cell sur-
face after 24 h from transfection. Transfected LOVO cells 
showed a reduction of 35% and 45% migration and invasion, 
respectively, as compared with non-transfected cells. Simi-
larly, in WIDR cells, transfection caused an about 70% and 
80% decrease of motility and invasion.After 48h, urantide 
(100 nM) induced an about 50% decrease of both migratory 
and invasive properties in WIDR cells and LOVO cells, 
whereas treatment of anti-UTR shRNA-transfected LOVO 
and WIDR cells with 100 nM urantide did not cause any 
advantage in terms of motility and invasion inhibition. From 
these observations, it is possible to deduce that, in the initial 
steps of cancerogenesis process, the interaction U-II/UTR 
carries out an important role in the progression of neoplastic 
disease. Tumour tissue could produce a higher amount of U-
II, and at the same time, it could become more susceptible to 
U-II. This is related to a higher expression of both mRNA 
for UTR and UTR itself. Therefore U-II may be considered 
as autocrine and paracrine factor of tumour expression. 
Breast Cancer 
Breast cancer is the most frequent and deadliest cancer in 
U.S. women, resulting in an estimated 40,730 new deaths in 
2015 [86]. The stage of disease at the diagnosis influences 
long-term survival of breast tumor patients: the 5-year sur-
vival rate is 99% for localized disease, 85% for regional 
stage, and 25% for distant-stage tumor [87]. Therefore, at-
tempts to reduce breast cancer deaths have mainly relied on 
early cancer detection and treatment. Recently, a total of 59 
female patients with a diagnosis of breast cancer were en-
rolled and both UTR and U-II were immunohistochemically 
determined in tumour and normal tissues. U-II and UTR 
were expressed in 55 and 53 tumour samples, respectively, 
showing a strong positive correlation [65]. 
No statistically significant correlation was recorded be-
tween patient age and U-II [88] (p=0.71, r= –0250), but a 
statistically weak negative correlation was found between 
patient age and UTR (p=0.038, r= –0281). U-II and UTR 
were higher in the pre-menopausal patients. The only patho-
logical characteristic found to be correlated with both high 
UTR and U-II expression was the absence of extranodal in-
vasion in patients with lymph node metastases. U-II was 
significantly lower in patients with lymphatic invasion. 
Overall these findings suggest a role as good prognostic fac-
tor for both U-II and UTR in breast cancer even if studies on 
larger series of patients and correlation with survival data are 
strongly warranted to give definitive opinions [65]. In an-
other recent report, the role of U-II plasma levels 
and of the U-II gene polymorphisms was studied in breast 
cancer patients [89]. 
One hundred forty-nine breast cancer patients 
and 148 healthy subjects with age-matched characteristics 
were enrolled and U-II plasma levels and Thr21Met and 
Ser89Asn polymorphisms in UST2 gene were detected [89]. 
The authors found a significant decrease of the circulating 
protein levels in patients compared with healthy controls. 
Moreover, only Thr21Met polymorphism in UST2 gene 
was highly expressed in breast cancer patients with a statisti-
cally very high significance (p= 0.0001) [89]. As a whole, 
these data suggest that UTR and U-II expression in tumour 
tissues and U-II protein serum levels are good prognostica-
tors in breast cancer, whereas the occurrence of Thr21Met 
mutation in U-II is a strong predictor of tumour occurrence. 
Since UT-II may act as an autocrine/paracrine factor and is 
able to regulate invasion and migration, which represent two 
important steps in carcinogenesis, it plays a key role in tu-
mour biology of breast cancer. Particularly, Thr21Met poly-
morphism represents a risk factor because it increases breast 
cancer susceptibility, probably by affecting molecular 
mechanisms at the basis of the pathogenesis and develop-
ment of breast cancer. This polymorphism could affect the 
binding efficiency of U-II to its receptor thus reducing its 
paracrine or autocrine effects. 
Glioblastoma 
Glioblastoma [glioblastoma multiforme (GBM)] is the 
most frequent and aggressive form of adult primary central 
nervous system tumor. Treatment of GBM patients with sur-
gery, radiotherapy and chemotherapy improved median sur-
vival up-to 40–50 weeks. The combination of radiotherapy 
and temozolomide (TMZ) is recognized as the gold-standard 
first-line treatment for GBM [90, 91]. The promoter of the 
DNA repair gene O6-methylguanine-DNA methyltransferase 
resulted methylated in a group of patients with improved 
survival [92]. Despite the hard line therapy,tumors invariably 
relapse, median survival is 60-70 weeks and 5-years survival 
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Table 2.  Urotensin-II Receptor involvement in neoplastic diseases. 
Disease Involvement Evidence Drug Ref. 
Prostate Cancer 
U-II controls proliferation, invasion and motility of prostate cancer cells; inverse 
correlation between UTR expression and Gleason grade. 
Urantide [60] 
Prostate Cancer UTR expression was a significant predictor of Gleason upgrading ND [74] 
Bladder Cancer 
UTR controls proliferation, invasion and motility of bladder cancer cells; correla-
tion between UTR low expression and recurrence rate of NMIBC 
UPG84 [62] 
Hepatocellular Carcinoma 
In mice association between pre-cancerous lesions induced by the exposure to 
DEN and the level of plasmatic and tissue UTR and U-II expression was found 
ND [63] 
Hepatocellular Carcinoma 
Higher U-II and UTR mRNA and protein expression in cancer tissue than in 
healthy tissues of the same patients; U-II increased phosphorylated PKC, ERK, 
and p38 MAPK and stimulated cell growth 
ND [64] 
Colorectal Cancer 
UTR regulates proliferation, motility and invasion of colorectal  
cancer cells; Inverse correlation between UTR expression and colorectal  
cancer grading in vivo 
UPG83 and UPG85 [59] 
Breast Cancer 
U-II and UTR were expressed in 55 and 53 tumour samples, respectively. UTR 
and U-II expression correlated with absence of extranodal invasion. 
ND [65] 
Breast Cancer 
UTR and U-II expression in tumour tissues and U-II protein serum levels are 
good prognosticators, whereas the occurrence of Thr21Met mutation in U-II is a 
strong predictor of tumour onset. 
ND [56] 
Glioblastoma 
U-II behaves as a chemokine initiating directional cell migration through 
UT/G13 and Rho/ROCK 
ND [94] 
U-II: Urotensin-II; UTR: Urotensin-II Receptor; ET-1: Endothelin-1; NMIBC: non-muscle invasive bladder cancer; DEN: Diethylnitrosamine; ERK: Extracellular-signal-regulated 
kinase; MAPK: Mitogen-activated protein kinase; PKC: Protein kinase C; ROCK: RhoA/Rho kinase; ND: not detected. 
 
rate is less than 10%. Recently, it has been reported that 
UTR and Gamma-AminoButyric Acid Receptors (GAB-
AAR) are coexpressed in rat glial cells, in glioma cells and 
in human astrocytes, and that U-II inhibited the repressor 
activity of GABAAR in rat astrocytes. 
Moreover, UTR once activated, inhibited GABAAR 
function and induced its endocytosis in CHO and human 
astrocytes. This UII-mediated inhibition of the GABAergic 
activity may be involved in astrocyte growth and in glioma 
development [93]. U-II and its receptor have been recently 
studied in GBM and the authors found that intense U-II and 
UTR staining were detected in pseudopalissadic perinecrotic 
areas; moreover UII was also expressed in perivascular re-
gions that were positive for CD34. UTR was found in fresh 
explants from 8 different resected GBM, in many cancer 
cells, in explanted cells and in vascular regions. UTR and U-
II expression in human GBM cell lines suggested that 
UTR/U-II axis regulated tumor cells in auto/paracrine fash-
ion. The authors demonstrated that U-II works as a chemo-
tactic factor for GBM cells when a gradient of U-II concen-
tration was used, whereas U-II alone had no effects on the 
migratory properties of tumour cells. Moreover, they demon-
strated that U-II initiates cell migration by acting as 
chemokine and activating UT/ G13 and Rho/ROCK path-
ways, that include Gi/o and PhosphatidylInositol 3-Kinase 
(PI3K) components leading to Akt activation in GBM. 
The signalings induced by U-II/UTR axis are different 
for actin polymerization or lamellipodia formation. In fact, 
upon binding of U-II, UTR recruits G13 and Rho/ROCK 
signaling cascade for actin polymerization, activates a 
Gi/PI3K pathway for lamellipodia formation and UT/Gi/o 
pathway is engaged for focal point formation [94]. Moreo-
ver, the same authors demonstrated that U-II, by binding 
UTR, was able to induce β-arrestin 1/2 and G protein-
mediated (Gq, Gi, Go, G13) pathways, to trigger down-
stream pathways as ERK1/2 and to induce migration and 
adhesion in HEK cells [95]. U-II shows pleiotropic effects 
since its receptor couples to Gi, Go, Gq, and G13 and β-
arrestins and it is involved in the pathogenesis of several 
tumours. In native and tumoral glial cells UT is closely asso-
ciated to GABAAR. A cross-talk between UT and GABAAR 
could lead to the loss of the GABAAR expression in the 
plasma membrane. Moreover it would play a key role in the 
induction of cell proliferation by supporting transition from 
quiescent to proliferant astrocytes. Additionally, UT is able 
to act as a chemotaxis receptor and to activate specific trans-
ductional signals that are responsible for the switch between 
cell migration and adhesion by affecting molecular mecha-
nisms involved in tumour invasion. For a summary of the 
evidence of UTR involvement in cancers (Table 2).  
Agonists and Antagonists Generation: How to Modulate 
UTR Function 
Many design and development studies with agonists and 
antagonists of the octapeptide U-II(4-11) have been per-
formed in order to either block or stimulate UTR and its 
downstream signal transduction pathways. The development 
of the potent agonist, P5U [96] and the antagonist, named 
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Urantide (Urotensin Antagonist Peptide) [97] are valuable 
accomplishments of this. The substitution of Cys5residue in 
the fragment of U-II(4-11) [98] with Pen produced P5U pep-
tide, whose linear formula is the following: H-Asp-c[Pen-
Phe-Trp-Lys-Tyr-Cys]-Val-OH. In experiments evaluating 
contractive capacity in rat aorta, P5U has shown an about 20-
fold increase in potency compared to hU-II [96]. Optimiza-
tion of this lead compound has been aimed to stabilize spe-
cific conformation and to improve pharmacokinetic proper-
ties. Consistently, by chemical modification occurred on 
P5U sequence, Carotenuto et al. have recently performed the 
synthesis of an agonist more potent than P5U, by the re-
placement of Tyr9 residue with a benzothiazolylalanine resi-
due [99]. In previuos studies, P5U has been modified in posi-
tions 7 and 8, normally taken by Trp and Lys, respectively. 
The simulataneous substitution of Trp7 and Lys8 has driven 
to achievement of a potent antagonist, named Urantide, 
whose linear formula is: H-Asp-c[Pen-Phe-DTrp-Orn-Tyr-
Cys]-Val-OH. Urantide has become the reference compound 
used to evaluate antagonist activity [100, 101]. Among the 
strategies aimed at antagonizing UTR effects, it has been 
recently described the possibility to benefit from allosteric 
modulators of the receptor such as Urocontrin and Urocon-
trin A. These have allowed to discriminate the effects de-
rived from bindings of U-II or URP towards UTR due to the 
fact that they act as antagonists blocking the bond between 
U-II/URP and UTR through a non-competitive mechanism 
[102-104]. Although efforts to realize novel U-II derivatives 
have been successfully spent to provide more potent com-
pounds, the candidacy of such peptides as drugs remains 
limited due to their unfavourable pharmacokinetic properties. 
Attempts to overcome the drawbacks of their therapeutic use 
have been offered by the development of nonpeptide or pep-
tidomimetic molecules on the basis of pharmacophoric core 
sequence and secondary structure. Thus, different nonpeptide 
agonists (e.g. FL104, AC7954) and antagonists (e.g. Palo-
suran, SB-657510, GSK1562590 and GSK1440115) have 
been discovered and described in literature [105-108]. In 
general, all nonpeptide U-II analogues reported, normally 
preserve the three essential structural features, that is two 
aromatic rings and a basic group [109], which are necessary 
for the interaction with receptor counterpart. Moreover, pyr-
rolodiazepinones have been recently used as scaffolds to 
mimic the Bip-Lys-Tyr sequence of Urocontrin leading to 
new molecules able to selectively modulate U-II- and URP-
mediated biological activity [110]. An alternative and effi-
cient way to regulate the function of U-II/UTR axis is the 
downregulation and knock down of the receptor through the 
use of interference strategies. The delivery of siRNAs in 
tumour is an attractive and promising strategy that is becom-
ing more feasible through the use of nanocarriers. Indeed, 
nanocarriers can allow the selective accumulation of the 
siRNA in tumours through the so-called Enhanced Permea-
tion and Retention Effect (EPR). 
CONCLUSION 
U-IIUTR axis has been demonstrated to be involved in 
the regulation of blood pressure and blood pressure-
correlated disease [111, 112], however strong evidence sug-
gests its role in the regulation of proliferation and develop-
ment of several epithelial cancers. For a large number of 
oncological diseases taken into consideration in this review, 
it is necessary to identify a prognostic marker that must be 
independent of histological analysis performed by a patholo-
gist, influenced by his/her experience. This is important for 
the planning of more suitable therapies in relation to the de-
gree of neoplastic disease. The involvement of UTR expres-
sion in tumour tissues in the prediction of the clinical out-
come of the diseases alsosuggests its use as new prognostic 
factor in cancer illnesses. 
The existence of specific modulators of UTR activity and 
the possible development of interference strategies make 
UTR as a possible new therapeutic target for the control of 
cancer diseases.  
LIST OF ABBREVIATIONS 
Akt = Protein kinase B 
AM = Adrenomedullin 
cAMP-PKA = Cyclic adenosine monophosphate-protein 
kinase A  
CD = Cluster of differentiation 
c-Src = Src kinase 
DAG = Diacylglycerol 
DEN = Diethylnitrosamine 
EGFR = Epidermal growth factor receptor 
EPR = Enhanced permeation and retention effect 
ERK = Extracellular signal regulated kinase 
ERK = Extracellular-signal-regulated kinase 
ERS = Endoplasmic reticulum stress 
ET-1 = Endothelin-1 
ETa = type a receptor endothelin 
ETb = Type b receptor endothelin 
FAK = Focal adhesion kinase 
GABAAR = Gamma-aminobutyric acid receptors 
GMB = Glioblastoma multiforme 
GMC = glomerular mesangial cells 
GPR = G protein coupled-receptor 
GSK-3beta = Glycogen synthase kinase 3 beta 
HCC = Human hepatocarcinoma 
HuCC = Human corpus cavernosous 
hU-II = Human Urotensin-II 
ICP = Intracavernous pressure 
IP3 = Inositol trisphosphate 
LAM = Lymphangioleiomyomatosis 
MAPK = Mitogen-activated protein kinase 
MEK = Mitogen-activated protein kinase kinase 
MIBC = muscle invasive bladder cancer 
MLCK = Myosin light chain kinase 
mPAP = Mean pulmonary arterial pressure 
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mTOR = Mammalian target of rapamycin 
NADPH = nicotinamide adenosine dinucleotide phos-
phate 
NHE-1 = Sodium/hydrogen exchanger 1 
NMIBC = non-muscle invasive bladder cancer 
PAH = Pulmonary arterial hypertension 
PI3K = PhosphatidylInositol 3-Kinase 
PKC = Protein kinase C 
PLC = Phospholipase C 
RCC = Rat corpus cavernosous 
RGS2 = Regulator of G-protein signaling 2 
ROCK = RhoA/Rho kinase 
RT-PCR = Real time polymerase chain reaction 
SEM = Scanning electron microscope 
shRNA = Short hairpin RNA 
SOCE = Store-operated Ca(2+) entry 
SST-14 = Somatostatin-14 
TMZ = Temozolomide 
U-II = Urotensin-II 
UIIKO = UII gene deletion in mice 
URP = Urotensin-II related peptide 
UTR = Urotensin-II receptor 
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